Abstract 12588: Inflammatory Pathways and High-Risk Coronary Plaque in Obstructive Coronary Artery Disease in The PROMISE Clinical Trial

• Published in: Circulation (New York, N.Y.) N.Y.), 2022-11, Vol.146 (Suppl_1), p.A12588-A12588
• Main Authors: Zhao, Elizabeth, Giamberardino, Stephanie, Pagidipati, Neha J, Voora, Deepak, Hoffmann, Udo, Karady, Julia, Ferencik, Maros, Foldyna, Borek, Douglas, Pamela S, Shah, Svati H
• Format: Article
• Language: English
• ISSN: 0009-7322; 1524-4539
• DOI: 10.1161/circ.146.suppl_1.12588

IntroductionTwo-thirds of CV events occur in patients without oCAD; vulnerable plaque (VP) has been implicated in its pathobiology. Inflammation plays a role in atherosclerosis, but the relationships between its pathways and related biomarkers in VP have not been comprehensively evaluated. MethodsThe PROMISE trial randomized 10,003 patients with stable outpatient chest pain to CTA for coronary imaging vs standard of care. In this substudy, we measured 92 inflammatory proteins using the Olink platform in 1788 PROMISE participants with core-lab interpreted CTA and biospecimens. Principal component analysis (PCA) was used for dimensionality reduction and protein PCA factors were tested for association with a high-risk composite (HRC) phenotype (composed ofoCAD, CAC>400, VP features and/or Leaman score>5). Significant PCA protein factors (FDR q < 0.05) were tested with individual HRC features. ResultsThe cohort was 53% female, had a mean age of 60, and 58% had a HRC phenotype. Of 12 PCA factors, three were significantly negatively associated and one was positively associated with HRC (Figure) including factors related to T-cell dependent responses (factor 6, p